Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares gapped up prior to trading on Friday . The stock had previously closed at $13.95, but opened at $13.60. Sangamo Therapeutics shares last traded at $13.65, with a volume of 724,185 shares trading hands.

A number of research analysts have issued reports on the company. Wedbush reiterated a “neutral” rating and issued a $4.00 target price (down previously from $6.00) on shares of Sangamo Therapeutics in a research report on Tuesday, May 16th. ValuEngine upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. BidaskClub cut Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Wells Fargo & Company reiterated an “outperform” rating and issued a $30.00 target price (up previously from $20.00) on shares of Sangamo Therapeutics in a research report on Tuesday. Finally, Zacks Investment Research upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 16th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. Sangamo Therapeutics currently has a consensus rating of “Hold” and an average target price of $14.20.

The firm has a 50 day moving average of $10.38 and a 200-day moving average of $7.22. The stock’s market cap is $1.12 billion.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.06. Sangamo Therapeutics had a negative return on equity of 38.49% and a negative net margin of 246.39%. The firm had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $5.82 million. During the same quarter last year, the firm posted ($0.38) EPS. The company’s revenue was up 124.3% compared to the same quarter last year. On average, equities analysts anticipate that Sangamo Therapeutics, Inc. will post ($0.82) EPS for the current year.

In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 11,474 shares of the firm’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $10.44, for a total value of $119,788.56. Following the sale, the vice president now owns 23,991 shares of the company’s stock, valued at approximately $250,466.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Curt A. Herberts III sold 15,000 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $15.00, for a total value of $225,000.00. Following the completion of the sale, the vice president now directly owns 15,833 shares in the company, valued at approximately $237,495. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,474 shares of company stock worth $494,789. Insiders own 8.10% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. HighTower Advisors LLC increased its position in shares of Sangamo Therapeutics by 0.3% during the 1st quarter. HighTower Advisors LLC now owns 39,405 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 100 shares during the last quarter. Blair William & Co. IL increased its position in shares of Sangamo Therapeutics by 4.3% during the 2nd quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 500 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Sangamo Therapeutics by 0.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 128,764 shares of the biopharmaceutical company’s stock valued at $670,000 after purchasing an additional 513 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Sangamo Therapeutics by 6.8% during the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 832 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Sangamo Therapeutics by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 267,293 shares of the biopharmaceutical company’s stock valued at $2,353,000 after purchasing an additional 1,558 shares during the last quarter. Hedge funds and other institutional investors own 63.43% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Sangamo Therapeutics, Inc. (SGMO) Shares Gap Up to $13.60” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/09/08/sangamo-therapeutics-inc-sgmo-shares-gap-up-to-13-60.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.